Copyright Reports & Markets. All rights reserved.

Global Cystic Fibrosis (CF) Therapeutics Market Size, Status and Forecast 2021-2027

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Cystic Fibrosis (CF) Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
    • 1.2.2 Pancreatic enzyme supplements
    • 1.2.3 Mucolytics
    • 1.2.4 Bronchodilators
    • 1.2.5 CFTR modulators
  • 1.3 Market by Application
    • 1.3.1 Global Cystic Fibrosis (CF) Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
    • 1.3.2 Oral drugs
    • 1.3.3 Inhaled drugs
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Cystic Fibrosis (CF) Therapeutics Market Perspective (2016-2027)
  • 2.2 Cystic Fibrosis (CF) Therapeutics Growth Trends by Regions
    • 2.2.1 Cystic Fibrosis (CF) Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
    • 2.2.2 Cystic Fibrosis (CF) Therapeutics Historic Market Share by Regions (2016-2021)
    • 2.2.3 Cystic Fibrosis (CF) Therapeutics Forecasted Market Size by Regions (2022-2027)
  • 2.3 Cystic Fibrosis (CF) Therapeutics Industry Dynamic
    • 2.3.1 Cystic Fibrosis (CF) Therapeutics Market Trends
    • 2.3.2 Cystic Fibrosis (CF) Therapeutics Market Drivers
    • 2.3.3 Cystic Fibrosis (CF) Therapeutics Market Challenges
    • 2.3.4 Cystic Fibrosis (CF) Therapeutics Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Cystic Fibrosis (CF) Therapeutics Players by Revenue
    • 3.1.1 Global Top Cystic Fibrosis (CF) Therapeutics Players by Revenue (2016-2021)
    • 3.1.2 Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Players (2016-2021)
  • 3.2 Global Cystic Fibrosis (CF) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Cystic Fibrosis (CF) Therapeutics Revenue
  • 3.4 Global Cystic Fibrosis (CF) Therapeutics Market Concentration Ratio
    • 3.4.1 Global Cystic Fibrosis (CF) Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Cystic Fibrosis (CF) Therapeutics Revenue in 2020
  • 3.5 Cystic Fibrosis (CF) Therapeutics Key Players Head office and Area Served
  • 3.6 Key Players Cystic Fibrosis (CF) Therapeutics Product Solution and Service
  • 3.7 Date of Enter into Cystic Fibrosis (CF) Therapeutics Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Cystic Fibrosis (CF) Therapeutics Breakdown Data by Type

  • 4.1 Global Cystic Fibrosis (CF) Therapeutics Historic Market Size by Type (2016-2021)
  • 4.2 Global Cystic Fibrosis (CF) Therapeutics Forecasted Market Size by Type (2022-2027)

5 Cystic Fibrosis (CF) Therapeutics Breakdown Data by Application

  • 5.1 Global Cystic Fibrosis (CF) Therapeutics Historic Market Size by Application (2016-2021)
  • 5.2 Global Cystic Fibrosis (CF) Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America

  • 6.1 North America Cystic Fibrosis (CF) Therapeutics Market Size (2016-2027)
  • 6.2 North America Cystic Fibrosis (CF) Therapeutics Market Size by Type
    • 6.2.1 North America Cystic Fibrosis (CF) Therapeutics Market Size by Type (2016-2021)
    • 6.2.2 North America Cystic Fibrosis (CF) Therapeutics Market Size by Type (2022-2027)
    • 6.2.3 North America Cystic Fibrosis (CF) Therapeutics Market Size by Type (2016-2027)
  • 6.3 North America Cystic Fibrosis (CF) Therapeutics Market Size by Application
    • 6.3.1 North America Cystic Fibrosis (CF) Therapeutics Market Size by Application (2016-2021)
    • 6.3.2 North America Cystic Fibrosis (CF) Therapeutics Market Size by Application (2022-2027)
    • 6.3.3 North America Cystic Fibrosis (CF) Therapeutics Market Size by Application (2016-2027)
  • 6.4 North America Cystic Fibrosis (CF) Therapeutics Market Size by Country
    • 6.4.1 North America Cystic Fibrosis (CF) Therapeutics Market Size by Country (2016-2021)
    • 6.4.2 North America Cystic Fibrosis (CF) Therapeutics Market Size by Country (2022-2027)
    • 6.4.3 United States
    • 6.4.3 Canada

7 Europe

  • 7.1 Europe Cystic Fibrosis (CF) Therapeutics Market Size (2016-2027)
  • 7.2 Europe Cystic Fibrosis (CF) Therapeutics Market Size by Type
    • 7.2.1 Europe Cystic Fibrosis (CF) Therapeutics Market Size by Type (2016-2021)
    • 7.2.2 Europe Cystic Fibrosis (CF) Therapeutics Market Size by Type (2022-2027)
    • 7.2.3 Europe Cystic Fibrosis (CF) Therapeutics Market Size by Type (2016-2027)
  • 7.3 Europe Cystic Fibrosis (CF) Therapeutics Market Size by Application
    • 7.3.1 Europe Cystic Fibrosis (CF) Therapeutics Market Size by Application (2016-2021)
    • 7.3.2 Europe Cystic Fibrosis (CF) Therapeutics Market Size by Application (2022-2027)
    • 7.3.3 Europe Cystic Fibrosis (CF) Therapeutics Market Size by Application (2016-2027)
  • 7.4 Europe Cystic Fibrosis (CF) Therapeutics Market Size by Country
    • 7.4.1 Europe Cystic Fibrosis (CF) Therapeutics Market Size by Country (2016-2021)
    • 7.4.2 Europe Cystic Fibrosis (CF) Therapeutics Market Size by Country (2022-2027)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size (2016-2027)
  • 8.2 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size by Type
    • 8.2.1 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size by Type (2016-2021)
    • 8.2.2 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size by Type (2022-2027)
    • 8.2.3 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size by Type (2016-2027)
  • 8.3 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size by Application
    • 8.3.1 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size by Application (2016-2021)
    • 8.3.2 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size by Application (2022-2027)
    • 8.3.3 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size by Application (2016-2027)
  • 8.4 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size by Region
    • 8.4.1 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size by Region (2016-2021)
    • 8.4.2 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size by Region (2022-2027)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America Cystic Fibrosis (CF) Therapeutics Market Size (2016-2027)
  • 9.2 Latin America Cystic Fibrosis (CF) Therapeutics Market Size by Type
    • 9.2.1 Latin America Cystic Fibrosis (CF) Therapeutics Market Size by Type (2016-2021)
    • 9.2.2 Latin America Cystic Fibrosis (CF) Therapeutics Market Size by Type (2022-2027)
    • 9.2.3 Latin America Cystic Fibrosis (CF) Therapeutics Market Size by Type (2016-2027)
  • 9.3 Latin America Cystic Fibrosis (CF) Therapeutics Market Size by Application
    • 9.3.1 Latin America Cystic Fibrosis (CF) Therapeutics Market Size by Application (2016-2021)
    • 9.3.2 Latin America Cystic Fibrosis (CF) Therapeutics Market Size by Application (2022-2027)
    • 9.3.3 Latin America Cystic Fibrosis (CF) Therapeutics Market Size by Application (2016-2027)
  • 9.4 Latin America Cystic Fibrosis (CF) Therapeutics Market Size by Country
    • 9.4.1 Latin America Cystic Fibrosis (CF) Therapeutics Market Size by Country (2016-2021)
    • 9.4.2 Latin America Cystic Fibrosis (CF) Therapeutics Market Size by Country (2022-2027)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size (2016-2027)
  • 10.2 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size by Type
    • 10.2.1 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size by Type (2016-2021)
    • 10.2.2 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size by Type (2022-2027)
    • 10.2.3 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size by Type (2016-2027)
  • 10.3 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size by Application
    • 10.3.1 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size by Application (2016-2021)
    • 10.3.2 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size by Application (2022-2027)
    • 10.3.3 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size by Application (2016-2027)
  • 10.4 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size by Country
    • 10.4.1 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size by Country (2016-2021)
    • 10.4.2 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size by Country (2022-2027)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 Vertex Pharmaceuticalsorporated
    • 11.1.1 Vertex Pharmaceuticalsorporated Company Details
    • 11.1.2 Vertex Pharmaceuticalsorporated Business Overview
    • 11.1.3 Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Introduction
    • 11.1.4 Vertex Pharmaceuticalsorporated Revenue in Cystic Fibrosis (CF) Therapeutics Business (2016-2021)
    • 11.1.5 Vertex Pharmaceuticalsorporated Recent Development
  • 11.2 Gilead
    • 11.2.1 Gilead Company Details
    • 11.2.2 Gilead Business Overview
    • 11.2.3 Gilead Cystic Fibrosis (CF) Therapeutics Introduction
    • 11.2.4 Gilead Revenue in Cystic Fibrosis (CF) Therapeutics Business (2016-2021)
    • 11.2.5 Gilead Recent Development
  • 11.3 AbbVie,
    • 11.3.1 AbbVie, Company Details
    • 11.3.2 AbbVie, Business Overview
    • 11.3.3 AbbVie, Cystic Fibrosis (CF) Therapeutics Introduction
    • 11.3.4 AbbVie, Revenue in Cystic Fibrosis (CF) Therapeutics Business (2016-2021)
    • 11.3.5 AbbVie, Recent Development
  • 11.4 Novartis AG
    • 11.4.1 Novartis AG Company Details
    • 11.4.2 Novartis AG Business Overview
    • 11.4.3 Novartis AG Cystic Fibrosis (CF) Therapeutics Introduction
    • 11.4.4 Novartis AG Revenue in Cystic Fibrosis (CF) Therapeutics Business (2016-2021)
    • 11.4.5 Novartis AG Recent Development
  • 11.5 F. Hoffmann-La Roche Ltd
    • 11.5.1 F. Hoffmann-La Roche Ltd Company Details
    • 11.5.2 F. Hoffmann-La Roche Ltd Business Overview
    • 11.5.3 F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Introduction
    • 11.5.4 F. Hoffmann-La Roche Ltd Revenue in Cystic Fibrosis (CF) Therapeutics Business (2016-2021)
    • 11.5.5 F. Hoffmann-La Roche Ltd Recent Development
  • 11.6 Alaxia
    • 11.6.1 Alaxia Company Details
    • 11.6.2 Alaxia Business Overview
    • 11.6.3 Alaxia Cystic Fibrosis (CF) Therapeutics Introduction
    • 11.6.4 Alaxia Revenue in Cystic Fibrosis (CF) Therapeutics Business (2016-2021)
    • 11.6.5 Alaxia Recent Development
  • 11.7 Merck & Co.
    • 11.7.1 Merck & Co. Company Details
    • 11.7.2 Merck & Co. Business Overview
    • 11.7.3 Merck & Co. Cystic Fibrosis (CF) Therapeutics Introduction
    • 11.7.4 Merck & Co. Revenue in Cystic Fibrosis (CF) Therapeutics Business (2016-2021)
    • 11.7.5 Merck & Co. Recent Development
  • 11.8 AIT (Advanced Inhalation Therapies)
    • 11.8.1 AIT (Advanced Inhalation Therapies) Company Details
    • 11.8.2 AIT (Advanced Inhalation Therapies) Business Overview
    • 11.8.3 AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Introduction
    • 11.8.4 AIT (Advanced Inhalation Therapies) Revenue in Cystic Fibrosis (CF) Therapeutics Business (2016-2021)
    • 11.8.5 AIT (Advanced Inhalation Therapies) Recent Development
  • 11.9 ALLERGAN
    • 11.9.1 ALLERGAN Company Details
    • 11.9.2 ALLERGAN Business Overview
    • 11.9.3 ALLERGAN Cystic Fibrosis (CF) Therapeutics Introduction
    • 11.9.4 ALLERGAN Revenue in Cystic Fibrosis (CF) Therapeutics Business (2016-2021)
    • 11.9.5 ALLERGAN Recent Development
  • 11.10 AstraZeneca
    • 11.10.1 AstraZeneca Company Details
    • 11.10.2 AstraZeneca Business Overview
    • 11.10.3 AstraZeneca Cystic Fibrosis (CF) Therapeutics Introduction
    • 11.10.4 AstraZeneca Revenue in Cystic Fibrosis (CF) Therapeutics Business (2016-2021)
    • 11.10.5 AstraZeneca Recent Development
  • 11.11 Teva Pharmaceutical Industries Ltd
    • 11.11.1 Teva Pharmaceutical Industries Ltd Company Details
    • 11.11.2 Teva Pharmaceutical Industries Ltd Business Overview
    • 11.11.3 Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Introduction
    • 11.11.4 Teva Pharmaceutical Industries Ltd Revenue in Cystic Fibrosis (CF) Therapeutics Business (2016-2021)
    • 11.11.5 Teva Pharmaceutical Industries Ltd Recent Development
  • 11.12 Alcresta
    • 11.12.1 Alcresta Company Details
    • 11.12.2 Alcresta Business Overview
    • 11.12.3 Alcresta Cystic Fibrosis (CF) Therapeutics Introduction
    • 11.12.4 Alcresta Revenue in Cystic Fibrosis (CF) Therapeutics Business (2016-2021)
    • 11.12.5 Alcresta Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Cystic Fibrosis (CF) Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Cystic Fibrosis (CF) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

    Segment by Type
    Pancreatic enzyme supplements
    Mucolytics
    Bronchodilators
    CFTR modulators

    Segment by Application
    Oral drugs
    Inhaled drugs

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia
    Latin America
    Mexico
    Brazil
    Rest of Latin America
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of MEA

    By Company
    Vertex Pharmaceuticalsorporated
    Gilead
    AbbVie,
    Novartis AG
    F. Hoffmann-La Roche Ltd
    Alaxia
    Merck & Co.
    AIT (Advanced Inhalation Therapies)
    ALLERGAN
    Novartis AG
    F. Hoffmann-La Roche Ltd

    Buy now